Composition 0.1% to 2%
Observations for this pharmaceutical form can be found on the lists:WHO Model List of Essential Medicines
13.4. Medicines affecting skin differentiation and proliferation
The Expert Committee has requested a review of the comparative effectiveness and safety, for possible deletion of this medicine at its next meeting.